Clinical trial NCT02534519: Whole Genome Sequencing for Blood Group Genotyping and Definition as Exemplified on U- and St(a)+.
Official title: Applicability of Whole Genome Sequencing for Human Blood Group Genotyping and Genetic Definition of New Alleles as Exemplified on References and the Two MNSs-variants: U- and Stones(a)+
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Genetic Blood Group (bg) Polymorphism in U Negativity and St(a) of MNSs
Lead sponsor: Blood Donation Service Zurich, SRC
Sponsor class: OTHER
First posted: 2015-08-27
Enrollment: 8
Sex: ALL
Minimum age (years): 1
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Sampling method: PROBABILITY_SAMPLE
Study population: Genomic DNA of 2 U- samples were both provided as blinded reference material from New York and Vienna blood centres, respectively. Both donors are lost for follow up, and although there is no documented evidence for refusal of the respective donors to use their material in research projects, samples still lack informed consent. Additional reference samples (n max=4), and samples with suspected Stones(a)+ (n max=4) will be recruited from Zurich blood donors with informed consent, only

Brief summary: No health condition(s) are studied. Genetic background of blood groups is studied. U- and Stones(a)+ ("Caucasian type") are used as proof-of-principle samples. Disease associations of all blood group genes investigated are very rare, e.g. \< 1 among 1'000 Swiss individuals (see table 1), and are not to be expected in the course of this study.

Genomic DNA of 2 U- samples were both provided as blinded reference material from New York and Vienna blood centres, respectively. Both donors are lost for follow up, and although there is no documented evidence for refusal of the respective donors to use their material in research projects, samples still lack informed consent.

Detailed description: All 34 human blood group systems have at least two antithetical antigens and are of potential relevance during pregnancy and transfusion. Fortunately for every day routine practice, immunizations to foreign antigens are rare. Still, incompatibilities may occur in all blood group systems and will then require typing for the respective blood group antigens.

Blood genotyping evolved as the method of choice, in cases when typing reagents are commercially unavailable, or blood is inaccessible (foetus). In databases, most entries of blood group genes lack representative polymorphism (e.g. number of alleles). Moreover, many blood group antigens are insufficiently described in their intronic and inter-genetic sequences. This is true for results of unequal crossing-overs, gene-conversions and large insertions/deletions between highly homologous genes, especially within the blood group systems of Rhesus, e.g. RhD/RhCE and MN/Ss, respectively. Only Whole Genome Sequencing (WGS) allows for resolution of both problems: it delivers the whole blood group genome of an individual, and simultaneously recognizes new blood group alleles, or haplotypes. This request for ethical approval wants to test this assumption.

The antigenic determinants U- and Stones(a)+ of the blood group system MNSs still lack full genetic description and will serve as challenging examples for the description of new alleles (haplotypes) caused by large ins/del mutations of the two highly homologous genes GYPA and B. Genomic DNA of 2 U- samples were both provided as blinded reference material from New York and Vienna blood centres, respectively. Both donors are lost for follow up, and although there is no documented evidence for refusal of the respective donors to use their material in research projects, samples still lack informed consent. Additional reference samples (n max=4), and samples with suspected Stones(a)+ (n max=4) will be recruited from Zurich blood donors with informed consent, only.

Eligibility criteria: Inclusion Criteria:

* Existing biomaterial (gDNA), or
* Existing health related data for blood group U- (n max=2) and eligible for (venous) blood sampling of 20 mL, or
* Existing blood group pheno- and genotyping data indicating St(a)+ and eligible for (venous) blood sampling of 20 mL (n max=2), or
* Adequate blood group profile serving as reference (n max =4 \& n max =4'000) and eligible for (venous) blood sampling of 20 mL.

Exclusion Criteria:

* Ineligible for venous blood sampling of approx. 20 mL.

Primary outcomes:
measure: Whole Genome Sequencing for the definition of genetic background for blood group antigens U-, St(a)+
timeFrame: 2 year period
Secondary outcomes:
Other outcomes:
Locations:
city: Schlieren
country: Switzerland
facility: Blutpende Zürich, Dienstleistungszentrum
state: Zürich
Study officials:
affiliation: Blutspende Zürich, Dienstleistungszentrum
name: Christoph Gassner, PhD
role: PRINCIPAL_INVESTIGATOR
References: